Myricetin: targeting signaling networks in cancer and its implication in chemotherapy

Abstract

The gaps between the complex nature of cancer and therapeutics have been narrowed down due to extensive research in molecular oncology. Despite gathering massive insight into the mysteries of tumor heterogeneity and the molecular framework of tumor cells, therapy resistance and adverse side effects of current therapeutic remain the major challenge. This has shifted the attention towards therapeutics with less toxicity and high efficacy. Myricetin a natural flavonoid has been under the spotlight for its anti-cancer, anti-oxidant, and anti-inflammatory properties. The cutting-edge molecular techniques have shed light on the interplay between myricetin and dysregulated signaling cascades in cancer progression, invasion, and metastasis. However, there are limited data available regarding the nano-delivery platforms composed of myricetin in cancer. In this review, we have provided a comprehensive detail of myricetin-mediated regulation of different cellular pathways, its implications in cancer prevention, preclinical and clinical trials, and its current available nano-formulations for the treatment of various cancers.

Biosensing chips for cancer diagnosis and treatment: a new wave towards clinical innovation

“…Limitations of tumor biomarker-based detection in clinical cases derive from not discovering all the mutations and pathways involved in oncogenesis; as well as the mechanisms that allow the tumor to evade the immune system response, as data show that activation of oncogenesis pathways leads to immune system impairment [3,72,73]. Significant effort will be needed in the coming years to define and validate biomarkers that allow patient selection for personalized cancer management [74][75][76][77].…”

Recent updates on anticancer mechanisms of polyphenols

“…That is to say, the healthy cells of the human body collaborate on a structural and functional level to maintain the homeostasis and architecture of the body. Alteration of signaling pathways and mechanisms can influence the rate of cell proliferation and the risk of benign or malignant cell proliferation ( Ali et al, 2022 ; Hossain et al, 2022 ; Javed et al, 2022 ). Transformed cells acquire new properties that can have a significant impact on local structures or the whole organism.…”

“…The capability of cancer cells to avoid cell death activation, persistent angiogenesis, tissue invasion, and metastasis is unrivalled ( Docea et al, 2012 ; Mitrut et al, 2016 ). Considering this, metastasis is one of the primary causes of cancer-related mortality ( Javed et al, 2022 ). However, a big part of cancer-related fatalities can be mitigated or averted by avoiding risk factors and following evidence-based preventative interventions ( Hossain et al, 2022 ; Kitic et al, 2022 ).…”

Myricetin as a Potential Adjuvant in Chemotherapy: Studies on the Inhibition of Human Glutathione Transferase A1–1

“…In addition, MYR has been shown to affect cancer cells through diverse mechanisms. For example, it suppresses cancer cell invasion and metastasis, induces cell cycle arrest and apoptosis, and inhibits cell proliferation [ 25 , 26 , 27 ]. Furthermore, MYR has been shown to promote apoptosis by regulating Bcl−2 proteins, MAPK, and Wnt/ β -catenin signaling, and by stimulating ROS-mediated stress, endoplasmic reticulum stress, and DNA damage [ 21 , 22 , 23 , 24 ].…”

“…MYR is also involved in modulating other cell pathways such as PI3K/Akt pathway, Nrf2 signaling, mTOR pathway, Ras/Raf pathway, and JAK/STAT pathway and Btk [ 28 ]. MYR has also been shown to regulate the expression of inflammatory factors, induce protective autophagy, induce cell cycle arrest, inhibit cell invasion, and inhibit migration [ 24 , 25 , 26 ]. Several studies have demonstrated the in vitro role in MYR in chemoresistance.…”